
1. malar j. 2018 feb 1;17(1):57. doi: 10.1186/s12936-017-2139-7.

cyp2d6 activity risk recurrence plasmodium vivax malaria the
brazilian amazon: prospective cohort study.

brasil lw(1)(2), rodrigues-soares f(2), santoro ab(3), almeida acg(1)(2), kühn
a(1), ramasawmy r(1)(2)(4), lacerda mvg(1)(2)(5), monteiro wm(1)(2)(4),
suarez-kurtz g(6).

author information: 
(1)diretoria de ensino e pesquisa, fundação de medicina tropical dr. heitor
vieira dourado, manaus, am, brazil.
(2)programa de pós-graduação em medicina tropical, universidade estado do
amazonas, manaus, am, brazil.
(3)coordenação de pesquisa, instituto nacional de câncer, rio de janeiro, rj,
20231-050, brazil.
(4)faculdade de medicina, universidade nilton lins, manaus, am, brazil.
(5)instituto leônidas & maria deane, fiocruz, manaus, am, brazil.
(6)coordenação de pesquisa, instituto nacional de câncer, rio de janeiro, rj,
20231-050, brazil. kurtz@inca.gov.br.

background: cyp2d6 pathway mediates activation primaquine active
metabolite(s) hepatocytes. cyp2d6 highly polymorphic, encoding cyp2d6
isoforms normal, reduced, null increased activity. hypothesized
that plasmodium vivax malaria patients defective cyp2d6 function would at
increased risk primaquine failure prevent recurrence. aim this
study investigate association cyp2d6 polymorphisms inferred
cyp2d6 phenotypes malaria recurrence patients western brazilian 
amazon, following chloroquine/primaquine combined therapy.
methods: prospective cohort consisted p. vivax malaria patients were
followed 6 months completion chloroquine/primaquine therapy.
recurrence defined one malaria episodes, 28-180 days the
initial episode. genotyping nine cyp2d6 snps copy number variation was
performed using taqman assays fast 7500 real-time system. cyp2d6 star
alleles (haplotypes), diplotypes cyp2d6 phenotypes inferred, the
activity score system used define functionality cyp2d6
diplotypes. cyp2d6 activity scores (as) dichotomized at ≤ 1 (gpm, gim and
gnm-s phenotypes) and ≥ 1.5 (gnm-f gum phenotypes).
results: genotyping successfully performed 190 patients (44 with
recurrence 146 without recurrences). recurrence incidence higher in
individuals presenting reduced activity cyp2d6 phenotypes (adjusted relative
risk = 1.89, 95% ci 1.01-3.70; p = 0.049). attributable risk population
attributable fraction 11.5 9.9%, respectively. time elapsed the
first p. vivax malaria episode recurrence differ between
patients of ≤ 1 versus ≥ 1.5 (p = 0.917).
conclusions: results suggest cyp2d6 polymorphisms associated with
increased risk recurrence vivax malaria, following chloroquine-primaquine
combined therapy. association interpreted result reduced
conversion primaquine active metabolites patients reduced
cyp2d6 enzymatic activity.

doi: 10.1186/s12936-017-2139-7 
pmcid: pmc5795836
pmid: 29390987  [indexed medline]

